BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21796759)

  • 1. Hot-topic debate on kidney function: renal-sparing approaches are beneficial.
    Durand F
    Liver Transpl; 2011 Nov; 17 Suppl 3():S43-9. PubMed ID: 21796759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hot-topic debate on kidney function: renal-sparing approaches are ineffective.
    Lake JR
    Liver Transpl; 2011 Nov; 17 Suppl 3():S50-3. PubMed ID: 21898771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I; Chan L
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunosuppression in liver transplantation: renoprotective regimens].
    Serrano Aulló MT; Parra Moncasi E; Lorente Pérez S
    Gastroenterol Hepatol; 2011; 34(6):422-7. PubMed ID: 21458889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation.
    Saner FH; Cicinnati VR; Sotiropoulos G; Beckebaum S
    Liver Int; 2012 Feb; 32(2):179-88. PubMed ID: 21745304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
    Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function outcome in pediatric liver transplant recipients.
    Mention K; Lahoche-Manucci A; Bonnevalle M; Pruvot FR; Declerck N; Foulard M; Gottrand F
    Pediatr Transplant; 2005 Apr; 9(2):201-7. PubMed ID: 15787794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
    Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
    Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
    Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S; Eason J; Loss G
    Liver Transpl; 2003 Feb; 9(2):126-9. PubMed ID: 12548505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation.
    Furmańczyk A; Komuda-Leszek E; Durlik M
    Ann Transplant; 2009; 14(4):47-51. PubMed ID: 20009155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ; Shankel T; Deming D; Cutler D; Sahney S; Fitts J; Chinnock RE
    Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal-sparing strategies in cardiac transplantation.
    Gustafsson F; Ross HJ
    Curr Opin Organ Transplant; 2009 Oct; 14(5):566-70. PubMed ID: 19542890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.